Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of drug utilization pattern of antidiabetic drugs and 10-year cardiovascular risk in new and recently diagnosed type 2 diabetes mellitus patients: a prospective, longitudinal, observational, hospital-based study

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Purpose

To evaluate changes in drug utilization pattern of antidiabetic drugs on prospective follow-up of new and recently diagnosed type 2 diabetes mellitus patients along with their 10-year cardiovascular risk assessment.

Methods

A prospective observational hospital-based study was conducted among new and recently diagnosed (≤ 6 months) type 2 diabetes patients attending the medicine outpatient department (OPD) at tertiary care teaching hospital, Raipur, after taking written informed consent. Antidiabetic drug prescription and socio-demographic characteristics were noted in the Case Record Form. Recruited patients were followed up at 3, 6, and 9 months. Ten-year cardiovascular risk was determined using the QRISK®3 risk calculator.

Result

A total of 90 patients, 48 (53.33%) new and 42 (46.67%) recently diagnosed type 2 diabetes patients, were recruited. An average number of antidiabetic drugs prescribed in patients was 2.1 at the final visit. The average daily dose of antidiabetic drugs was assessed against the WHO/ATC-defined daily dose (DDD). It was decreased for metformin and other antidiabetic drugs, except for glimepiride. More than one-third of patients had a QRISK3 score >10% at each visit.

Conclusion

This study highlighted that patient education and periodic review of prescription of new and recently diagnosed diabetic patients play a vital role in managing type 2 diabetes mellitus by tailoring treatment regimen. The present study revealed overtreatment of low-risk groups and under-treatment of high-risk groups based on QRISK3 score and statins. This observation signifies that risk stratification is essential for preventing CVD risks in new diabetic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

Abbreviations

ADA:

American Diabetes Association

A1C:

hemoglobin A1C

AHA/ACC:

American Heart Association/American College of Cardiology

ASCVD:

atherosclerotic cardiovascular disease

CAD:

coronary artery disease

CV:

cardiovascular

DM:

diabetes mellitus

FDC:

fixed dose combination

NLEM:

National List of Essential Medicine

References

  1. Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9–16.

    Article  CAS  PubMed  Google Scholar 

  2. Orchard TJ, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA, 2015, 313:45–53. [PMCID: PMC4306335. https://doi.org/10.1001/jama.2014.16107 ]

  3. Press J, Jaacks LM, Mohan V, et al. Variation in health system performance for managing diabetes among states in India: a cross-sectional study of individuals aged 15 to 49 years. BMC Med. 2019;17(92). https://doi.org/10.1186/s12916-019-1325-6.

  4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703–713. [PMID: 9732337]

  5. American Diabetes Association; 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care 1 January 2021; 44 (Supplement_1): S125–S150. [10.2337/dc21-S010]

  6. Saleem SM. Modified Kuppuswamy Scale updated for year 2018. Paripex - Indian Journal of Research. 2018;7(3):2250–1991. https://doi.org/10.36106/paripex.

    Article  Google Scholar 

  7. Clin Risk Ltd. QRISK®3-2018 risk calculator https://qrisk.org/three (Last accessed: 21st December 2021).

  8. Cardiovascular disease: risk assessment and reduction, including lipid modification [https://www.nice.org.uk/guidance/cg181]

  9. WHO Collaborating Centre for Drug Statistics Methodology [https://www.whocc.no/atc_ddd_index ]

  10. Chaudhary PK, Singh SP, Pandey D, Ranjan K, Chaudhary R, Pratap B. A prospective study on drug utilization pattern of antidiabetic drugs in a tertiary care teaching hospital of eastern Uttar Pradesh, India. Int J Res Med Sci. 2019;7:669–75. https://doi.org/10.18203/2320-6012.ijrms20190915.

    Article  Google Scholar 

  11. Park K. Textbook of Preventive and Social Medicine. 25th ed. Jabalpur: M/s Banarsidas Bhanot;2019. In: Chapter 6, Epidemiology of chronic non-communicable diseases and conditions: diabetes mellitus. p. 423–4.

  12. Mandal S, et al. Drug utilization study in patients with type 2 diabetes mellitus attending diabetes clinic of a tertiary care hospital in rural Bengal. Int J Basic Clin Pharmacol. 2016;5(4):1647–54. https://doi.org/10.18203/2319-2003.ijbcp20162487.

    Article  Google Scholar 

  13. Geetha P, Shanmugasundharam P. Drug utilization evaluation of antidiabetic drugs among Type 2 diabetes patients of Tamil Nadu. Asian J Pharm Clin Res. 2017;10(9):202–5. https://doi.org/10.22159/ajpcr.2017.v10i9.19342.

    Article  CAS  Google Scholar 

  14. Sharma K, Santra S, Bhattacharya A, Agrawal D, Kumar S, Mishra SS. Study of utilization pattern and patient compliance of oral anti-hyperglycemic drugs in a tertiary care teaching hospital in Eastern India. J Obes Metab Res. 2015;2:221–7. https://doi.org/10.4103/2347-9906.170896.

    Article  Google Scholar 

  15. Satpathy SV, Datta S, Upreti B. Utilization study of antidiabetic agents in a teaching hospital of Sikkim and adherence to current standard treatment guidelines. J Pharm Bioall Sci. 2016;8:223–8. https://doi.org/10.4103/0975-7406.175975.

    Article  Google Scholar 

  16. Kapur A, Rehan HS, Gupta LK, Yadav M. Pattern of anti-diabetic drugs prescribed for type 2 diabetes mellitus patients in a tertiary care hospital of India: an observational study. Int J Basic Clin Pharmacol. 2019;8:1657–61. https://doi.org/10.18203/2319-2003.ijbcp20192667.

    Article  Google Scholar 

  17. Joshi DB, Lakhani JD, Siddhpuria RY, Tandel HP, Hajariwala NR. A study on drug utilization pattern of metformin and its different formulations used in patients with type-2 diabetes mellitus in tertiary care teaching hospital. J Integr Health Sci. 2018;6:22–6. https://doi.org/10.4103/JIHS.JIHS_15_18.

    Article  Google Scholar 

  18. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes.-2021. Diabetes Care. 2021;44:S111–24. https://doi.org/10.2337/dc21-S009.

    Article  Google Scholar 

  19. Alvin C. Powers and David D’Alessio. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia .In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 13th edition. New Delhi: McGraw-Hill; 2018; 2: p. 877-881

  20. Patel B, Oza B, Patel KP, Malhotra SD, Patel VJ. Pattern of antidiabetic drugs use in type-2 diabetic patients in a medicine outpatient clinic of a tertiary care teaching hospital. Int J Basic Clin Pharmacol. 2013;2:485–91. https://doi.org/10.5455/2319-2003.ijbcp20130826.

    Article  CAS  Google Scholar 

  21. Azimova K, San Juan Z, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. Ochsner J. 2014 ;14(4):616-632. [PMID: 25598727; PMCID: PMC4295739]

  22. Acharya KG, Shah KN, Solanki ND, Rana DA. Evaluation of antidiabetic prescriptions, cost and adherence to treatment guidelines: a prospective, cross-sectional study at a tertiary care teaching hospital. J Basic Clin Pharma. 2013;4:82–7. https://doi.org/10.4103/0976-0105.121653.

    Article  Google Scholar 

  23. Deb T, Chakrabarty A, Ghosh A. Adverse drug reactions in Type 2 diabetes mellitus patients on oral antidiabetic drugs in a diabetes outpatient department of a tertiary care teaching hospital in Eastern India. Int J Med Sci Public Health 2017;6(3):554-557. https://doi.org/10.5455/IJMSPH.2017.0423203102016 Corpus ID: 42897699]

  24. Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9:25. https://doi.org/10.1186/s13098-017-0225-1.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Finnikin S, Ryan R, Marshall T. Statin initiations and QRISK2 scoring in UK general practice. British Journal of General Practice. 2017;67:e881–7. https://doi.org/10.3399/bjgp17X693485.

    Article  Google Scholar 

  26. Van Staa TP, Smeeth L, Ng ES, et al. The efficiency of cardiovascular risk assessment: do the right patients get statin treatment? Heart. 2013;99(21):1597–602. https://doi.org/10.1136/heartjnl-2013-303698.

    Article  CAS  PubMed  Google Scholar 

  27. Hiran S, Singh A, Sial P. Cardiovascular risk stratification in new-onset diabetes by QRISK2 risk score and conventional risk score within 3 months of diagnosis of diabetes. J Diabetol. 2018;9:39–44. https://doi.org/10.4103/jod.jod_28_17CorpusID:79832683.

    Article  Google Scholar 

  28. ASCVD Risk Estimator + (acc.org) (Last accessed on 22nd December 2021)

Download references

Acknowledgements

We are highly thankful to Statistician Mr. Arvind Shukla for data analysis.

Funding

This study was not funded. The authors did not receive support from any organization for the submitted work.

Author information

Authors and Affiliations

  1. Department of Pharmacology, All India Institute of Medical Sciences, 2nd floor, College Building, Gate 5 GE Road, Tatibandh, Raipur, Chhattisgarh, 492099, India

    J. K. Mehta, S. P. Dhaneria, N. R. Gaikwad & Y. N. Keche

  2. Department of Medicine, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India

    P. N. Wasnik & M. S. Siddiqui

Authors
  1. J. K. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. P. Dhaneria
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. R. Gaikwad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. N. Keche
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. N. Wasnik
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. S. Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. K. Mehta.

Ethics declarations

Ethics approval

The study was a prospective, longitudinal, observational hospital-based study initiated after obtaining approval from Institute Ethics Committee. Written informed consent was obtained from all the patients.

Consent for publication

All patients provided written informed consent before study entry.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mehta, J.K., Dhaneria, S.P., Gaikwad, N.R. et al. Evaluation of drug utilization pattern of antidiabetic drugs and 10-year cardiovascular risk in new and recently diagnosed type 2 diabetes mellitus patients: a prospective, longitudinal, observational, hospital-based study. Int J Diabetes Dev Ctries 43, 59–65 (2023). https://doi.org/10.1007/s13410-022-01049-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-022-01049-4

Keywords

Search

Navigation